Between Excess and Agony: How We Failed the Sick

🇵🇱 Polski
Between Excess and Agony: How We Failed the Sick

📚 Based on

Markets of Pain: Opium, Capitalism, and the Global History of Painkillers ()
Oxford University Press
ISBN: 9780197527825

👤 About the Author

Benjamin Robert Siegel

Boston University

Benjamin Robert Siegel is an Associate Professor of History at Boston University, where he specializes in the history of global commodity systems and modern South Asia. A former journalist for Time magazine in New Delhi and Hong Kong, Siegel holds a Ph.D. in History from Harvard University and a B.A. from Yale University. His academic work explores the intersection of food, medicine, and state power, with a focus on how global supply chains shape modern life. He is the author of Hungry Nation: Food, Famine, and the Making of Modern India (2018) and Markets of Pain: Opium, Capitalism, and the Global History of Painkillers (2026). His research has been supported by fellowships from the American Council of Learned Societies and the Harvard Academy for International and Area Studies, and he has served as the Associate Chair of History at Boston University.

Introduction

The opioid crisis is not merely an American pathology, but a systemic failure of global pain management. This article examines how modern states and corporations, under the guise of patient care, have created a mechanism that generates mass addiction. The reader will learn why the current drug distribution system is deeply inequitable and how flawed drug policy assumptions lead to global disparities in access to pain relief.

The opioid crisis as a test of the system's moral accounting

The American crisis is the result of regulatory capture by pharmaceutical interests. It is not a local glitch, but a global failure in which pain has become a commodity and the patient a unit in a spreadsheet. The system failed because it allowed corporations to engage in systemic cynicism—transforming greed into a technology for distributing suffering. Historically, agro-industrial infrastructure (e.g., poppy cultivation in India or Tasmania) has been subordinated to the needs of major corporations, laying the foundation for a massive oversupply of drugs in wealthy nations.

The paradox of control: why restrictions fuel the black market

Tightening controls without providing medical care merely shifts demand to the black market. When the state restricts access to medication, addicted patients do not recover; instead, they turn to dangerous synthetics such as fentanyl or nitazenes. This is proof of the failure of the myth of control—the belief that bureaucratic prohibitions grant power over substances. Restrictive drug policies often stigmatize the sick, treating them as criminals, which leads to the systemic neglect of chronic pain patients who lose access to safe therapy.

The global weight of pain: between the death industry and agony

The global opioid system resembles a cruel scale: on one side lies an excess of pills in wealthy countries, and on the other, a tragic shortage of morphine in developing nations. This inequality stems from the fact that drug distribution is driven by profit rather than medical need. Historical attempts at regulation have not solved the problem of addiction, but have merely transformed the mechanisms of profit-seeking. To heal the system, we must move away from prohibition toward a policy of responsible accessibility, which combines strict marketing oversight with full access to pain treatment and harm reduction.

Summary

The history of opium is a mirror of modernity, reflecting our inability to fairly separate relief from greed. Fixing the system requires a paradigm shift: addiction must be treated as a biopsychosocial problem, not a moral failing. We must build institutions capable of operating within contradictions, where a drug is simultaneously a lifesaver and a threat. If we do not change the foundations of this moral accounting, every subsequent preparation will remain merely a tool for mass misery. Are we ready to prioritize human dignity over sales figures?

📄 Full analysis available in PDF

📖 Glossary

Moralna księgowość
Systemowe podejście, w którym etyka i ludzkie cierpienie są redukowane do suchych bilansów zysków, strat oraz procedur administracyjnych.
Zarządzanie bólem
Termin medyczny i administracyjny, który w kontekście kryzysu często maskuje komercjalizację ulgi w cierpieniu i traktowanie pacjenta jako jednostki popytu.
Nitazeny
Nowa klasa niezwykle silnych syntetycznych opioidów, znacznie trudniejszych do monitorowania i wykrycia niż tradycyjne substancje.
Paradoks kontroli
Zjawisko, w którym gwałtowne ograniczenie legalnej podaży leków bez wsparcia terapeutycznego wypycha osoby uzależnione na niebezpieczny czarny rynek.
Globalna nierówność bólu
Dysproporcja między nadmierną dostępnością opioidów w krajach bogatych a drastycznym brakiem podstawowych leków przeciwbólowych w krajach rozwijających się.
Syntetyczna substytucja
Proces zastępowania naturalnych surowców (jak mak) przez substancje wytwarzane w laboratoriach, co ułatwia przemyt i zwiększa ryzyko przedawkowania.

Frequently Asked Questions

What is 'moral accounting' in the context of the opioid crisis?
This is a term describing a system that, instead of focusing on actual aid, prioritizes efficient market management and optimizing the profits of pharmaceutical corporations at the expense of ethics.
Why hasn't tightening prescription controls solved the addiction problem?
The sudden cutoff from legal medications without providing alternative therapy has led patients to seek cheaper and more dangerous substitutes, such as heroin and fentanyl.
What is the paradox of global pain inequality?
It involves the tragic coexistence of two worlds: the wealthy North, where an excess of opioids kills thousands of people, and the poorer South, where patients die in agony due to a lack of morphine.
What new threats do nitazenes pose in 2025?
Nitazenes represent a new phase of synthetic threat; they are highly potent substances that, due to their chemical structure, are almost impossible to detect using traditional screening methods.
Does a 27 percent drop in U.S. deaths mean the crisis is over?
While this is a sign of hope, experts warn that the number of victims is still dramatically high and the synthetics market shows the ability to adapt quickly and create new threats.

Related Questions

🧠 Thematic Groups

Tags: opioid crisis pain management fentanyl nitazene pharmaceutical capitalism moral accounting global pain inequality synthetic opioids the paradox of control naloxone systemic hypocrisy morphine war on drugs cultural experience of pain pharmaceutical marketing